US EditionPublished • loading... • Updated
Pick GLP-1s as First Drug Option in Obesity, Guidelines From Abroad Say
EASO recommends semaglutide and tirzepatide as first-line obesity treatments based on trials showing average weight loss of 14.9% and 22.5%, respectively.
Summary by MedPage Today
Podcasts & Opinions
10 Articles
10 Articles
MedPage TodayReposted by 
Anti-Aging, Acupuncture and Health News
Anti-Aging, Acupuncture and Health NewsPick GLP-1s as First Drug Option in Obesity, Guidelines From Abroad Say
(MedPage Today) -- A new treatment algorithm from the European Association for the Study of Obesity (EASO) recommends opting for semaglutide (Wegovy) or tirzepatide (Zepbound) first when "substantial" weight loss is needed in a patient. The two...
·New York, United States
Read Full Article
The European Association for Obesity Research recommends that treatment with the active substances semaglutide and tirzepatide be the standard for the treatment of obesity. Although the means are expensive, the subsequent costs of the disease would be significantly higher.
der Standard ATReposted by 
Salzburger Nachrichten
Salzburger NachrichtenAccording to the new recommendation of the European Association for Obesity Research, syringes should be the first choice in case of severe weight loss
·Vienna, Austria
Read Full Article
Coverage Details
Total News Sources10
Leaning Left1Leaning Right2Center3Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 17%
C 50%
R 33%
Factuality
To view factuality data please Upgrade to Premium
